What is the long-term trend for Jazz Pharmaceuticals's derivative liabilities - fair value?

Over 5 years (2020 to 2025), Jazz Pharmaceuticals's derivative liabilities - fair value has grown at a 3.0% compound annual growth rate (CAGR), from $3.63M to $4.2M.

Jazz Pharmaceuticals JAZZ Derivative Liabilities - Fair Value

Derivative Liabilities - Fair Value at other companies

AmgenAMGN

——

BridgeBio PharmaBBIO

——

BiogenBIIB

——

ResMedRMD

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

See full

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

See full

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation

See full

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Profitability

See full

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Returns & leverage

See full

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's derivative liabilities - fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's derivative liabilities - fair value?: Jazz Pharmaceuticals (JAZZ) reported derivative liabilities - fair value of $8.5M in Q1 2026.
What is the long-term trend for Jazz Pharmaceuticals's derivative liabilities - fair value?: Over 5 years (2020 to 2025), Jazz Pharmaceuticals's derivative liabilities - fair value has grown at a 3.0% compound annual growth rate (CAGR), from $3.63M to $4.2M.